Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  SCYNEXIS Inc    SCYX

SCYNEXIS INC

(SCYX)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
04/12/2019 04/15/2019 04/16/2019 04/17/2019 04/18/2019 Date
1.83(c) 1.79(c) 1.76(c) 1.61(c) 1.65(c) Last
1 334 865 2 174 504 792 632 1 715 480 812 160 Volume
-1.08% -2.19% -1.68% -8.52% +2.48% Change
More quotes
Financials (USD)
Sales 2019 0,20 M
EBIT 2019 -39,9 M
Net income 2019 -40,7 M
Debt 2019 -
Yield 2019 -
Sales 2020 4,56 M
EBIT 2020 -38,2 M
Net income 2020 -38,8 M
Debt 2020 -
Yield 2020 -
P/E ratio 2019 -
P/E ratio 2020
Capi. / Sales2019 409x
Capi. / Sales2020 18,1x
Capitalization 82,7 M
More Financials
Company
SCYNEXIS, Inc. is engaged in the discovery, development and commercialization of anti-infectives. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of several fungal infections, including serious invasive fungal infections. SCY-078... 
Sector
Pharmaceuticals
Calendar
05/13Earnings Release
More about the company
Surperformance© ratings of SCYNEXIS Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on SCYNEXIS INC
04/15SCYNEXIS : to Discuss ECCMID 2019 Clinical Data, Including Successful Case Studi..
PR
04/12SCYNEXIS : Antimicrobials Working Group Highlights Member Company Participation ..
PR
04/08SCYNEXIS : Commends the New York Times for its Reporting on Candida auris and Ot..
PR
04/04SCYNEXIS : Ibrexafungerp Shows Favorable Clinical Activity in Resistant Fungal I..
AQ
04/03SCYNEXIS : Ibrexafungerp Shows Favorable Clinical Activity in Resistant Fungal I..
PR
04/01SCYNEXIS, INC. : to Present at Upcoming Investor Conferences
PR
03/14SCYNEXIS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESUL..
AQ
03/09SCYNEXIS : is Retiring Existing Term Loan Through a Lower-Interest and Longer-Te..
AQ
03/08SCYNEXIS INC : Entry into a Material Definitive Agreement, Creation of a Direct ..
AQ
03/07SCYNEXIS : is Retiring Existing Term Loan Through a Lower-Interest and Longer-Te..
PR
More news
Sector news : Pharmaceuticals - NEC
11:53aTEVA PHARMACEUTICAL INDUSTRIES : Pharma Gets FDA Approval to Market Generic Nasa..
DJ
04/18Pfizer, Lilly Release Top-Line Results From Phase 3 Study of Tanezumab for Os..
DJ
04/18Pfizer, Johnson & Johnson Weigh on Pharmaceutical ETFs
DJ
04/17ACREAGE : Canopy Growth nearing deal to buy U.S.-based pot company Acreage Holdi..
RE
04/17MERCK AND : on Pace for Largest Percent Decrease in Over a Year -- Data Talk
DJ
More sector news : Pharmaceuticals - NEC
Chart SCYNEXIS INC
Duration : Period :
SCYNEXIS Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SCYNEXIS INC
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Average target price 5,94 $
Spread / Average Target 260%
EPS Revisions
Managers
NameTitle
Marco Taglietti President, Chief Executive Officer & Director
Guy MacDonald Chairman
Eric Francois Chief Financial Officer
David Angulo Gonzalez Chief Medical Officer
Ann F. Hanham Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
SCYNEXIS INC242.54%83
JOHNSON & JOHNSON6.56%366 184
ROCHE HOLDING LTD.8.22%224 445
PFIZER-9.78%218 630
NOVARTIS3.69%194 472
MERCK AND COMPANY-4.21%189 055